Menopausal Hormone Therapy and the Risk for VTE, AD

Elliot, William T.
December 2012
OB/GYN Clinical Alert;Dec2012 Pharmacology Watch, p1
The article focuses on a study on the effect of menopausal hormone therapy (HT) on venous thromboembolism (VTE). It was found in the study that the timing of postmenopausal HT is critical in determining risk for Alzheimer's disease whereas it also has neuroprotective benefits if started immediately after menopause. It also informs about the drugs which are approved by the U.S. Food and Drug Administration for treating several disorders.


Related Articles

  • Menopausal Hormone Therapy and the Risk for VTE, AD. Elliott, William T. // Primary Care Reports;Dec2012 Pharmacology Watch, p1 

    The article discusses multiple healthcare and clinical research updates. It mentions that Estrogen-progesterone combination for menopausal hormone therapy (HT) elevates the risk of venous thromboembolism (VTE) while act as neuroprotective against Alzheimer's disease (AD). Topics including...

  • Menopausal Hormone Therapy and the Risk for VTE, AD.  // OB/GYN Clinical Alert;Dec2012, Vol. 29 Issue 8, p1 

    The article offers information on the determination of risk associated with venous thromboembolism (VTE) and Alzheimer's disease (AD). It includes information on the drug formulation of menopausal hormone therapy (HT) that can help in determination of the risk associated with VTE and AD. It...

  • HRT TAKES ANOTHER HIT. Song, Sora // Time;2/23/2004, Vol. 163 Issue 8, p66 

    Reports that hormone-replacement therapy may increase the risk of dementia in older women according to the U.S. Food & Drug Administration. Evidence from the 'Journal of the American Medical Association' that women taking Prempro doubled their risk of Alzheimer's; Link between HRT pills and an...

  • Lupin wins FDA tentative approval for Alzheimer's drug.  // PharmaWatch: CNS;Mar2010, Vol. 9 Issue 3, p7 

    No abstract available.

  • Generic Version of Namenda├é┬« Approved.  // Journal of Gerontological Nursing;2015, Vol. 41 Issue 10, p8 

    The article reports on the decision of the U.S. Food and Drug Administration (FDA) to approve the abbreviated new drug application submitted by Upsher-Smith Laboratories for its Memantine Hydrochloride tablets.

  • First drug approved for severe Alzheimer's. LoBuono, Charlotte // Drug Topics;11/17/2003, Vol. 147 Issue 22, p24 

    Reports on the U.S. Food and Drug Administration's approval of memantine for the treatment of moderate to severe Alzheimer's disease. Inhibition of excitotoxic effect by binding preferentially to N-methyl-D-aspartate receptors and blocking cation channels; Common adverse effects;...

  • Higher Dosage Of Aricept OK'd.  // Chain Drug Review;8/30/2010, Vol. 32 Issue 14, p33 

    The article reports on the approval of Aricept, a dopaminergic for the treatment of Alzheimer's diseases, comarketed by Eisai Inc. and Pfizer Inc., by the U.S. Food and Drug Administration (FDA).

  • Hormone replacement therapy linked to thromboembolism. Pinkowish, Mary Desmond // Patient Care for the Nurse Practitioner;Jul2000, Vol. 3 Issue 7, p15 

    Presents information on a study which examined the link of hormone replacement therapy to thromboembolism. Subjects used in the study; Findings; Analysis and commentary.

  • Thromboembolic Disease. Grady, D.; Wenger, N.K.; Herrington, D.; Brill-Edwards, P.; Ginsberg, J.S.; Gent, M. // Annals of Internal Medicine;1/15/2002, Vol. 136 Issue 2, p140 

    Examines the factors contributing to the occurrence of venous thromboembolism. Observations on the role of hormone replacement therapy in the development of venous thromboembolism; Increase risk of recurrence of thromboembolism on pregnant women; Drugs recommended for the treatment of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics